ArticleEpidemiology (Cambridge, Mass.)2019
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.
Article in Epidemiology (Cambridge, Mass.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2021Pooled it
- Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.JAMA network open · 2021Trial
- Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.Journal of neurology · 2026Article
- Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset - a matched cohort study.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Completeness and generalizability of the Swedish MS register.European journal of epidemiology · 2025Article
- Exploring Different Levels of Contact Frequency in Multiple Sclerosis Care.Brain and behavior · 2025Article
- Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.Journal of neurology, neurosurgery, and psychiatry · 2024Observational
- Work Adjustments by Types of Occupations Amongst People with Multiple Sclerosis: A Survey Study.Journal of occupational rehabilitation · 2024Article
- Exploring the working life of people with multiple sclerosis during the COVID-19 pandemic in Sweden.BMC public health · 2024Article
- Incidence rate and prevalence of pediatric-onset multiple sclerosis in Sweden: A population-based register study.European journal of neurology · 2024Article
- Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.Journal of neurology, neurosurgery, and psychiatry · 2024Observational
- The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event.Frontiers in neurology · 2024Review
- Disclosing or concealing multiple sclerosis in the workplace: two sides of the same coin-insights from a Swedish population-based survey.Frontiers in public health · 2024Article
- Excess costs of multiple sclerosis: a register-based study in Sweden.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Observational
- The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Deficit of homozygosity among 1.52 million individuals and genetic causes of recessive lethality.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Swedish Multiple Sclerosis Register is a national register monitoring treatment and clinical course for all Swedish multiple sclerosis (MS) patients, with high coverage and close integration with the clinic. Despite its great value for epidemiologic research, it has not previously been validated. In this brief report, we summarize a large validation of >3,000 patients in the register using clinical chart review in the context of the COMBAT-MS study. While further improving the data quality for a central cohort of patients available for future epidemiologic research, this study also allowed us to estimate the accuracy and completeness of the register data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.